Top Personalized Medicine Posts of 2016 (So Far) | Diaceutics

Top Personalized Medicine Posts of 2016 (So Far)

August 21st, 2016

While personalized medicine is what we at Diaceutics eat, sleep, and breathe, that’s not the case for everyone else, whether they be in pharma or just generally interested in health care, medicine and science. Luckily, we’ve got everyone covered. Now that we’re well into the second half of 2016, we’ve rounded up the top personalized medicine posts of the year so far so to keep you up to date on the important stuff.

Is Personalized Medicine Here?
A great dive into the possibilities provided by major technological advances in genomics, this is a must read for anyone interested in PM. Don’t be intimidated by the text-heavy content, this post moves quickly through several major points in a very effective way.

Analytics and Personalized Medicine – Just the Tip of the Iceberg

I loved this article as it is short and to the point – but more importantly it helps to send the message of personalized medicine to a much wider audience than the technical pharmaceutical reader.

Prioritization of Anticancer Drugs Against a Cancer Using Genomic Features of Cancer Cells: A Step Towards Personalized Medicine

This is not so much a post as it is an article reporting the highly fascinating results of a study. The study was based on “24 anticancer drugs tested against a large number of cell lines in order to understand the relation between drug resistance and altered genomic features of a cancer cell line.” In hopes of promoting patient-specific anticancer drugs and to aid the scientific community, the creators of this study have developed a tool for “predicting priority/potency of an anticancer drug against a cancer cell line using its genomic features.” The tool is called CancerDP and can be found at this address:

Personalized Medicine And Big Data: Opportunities And Pitfalls Of IT Innovation

I’m an analytical person and I love data, which made this article my favorite of the bunch. Getting granular with big data is possible, but to reach this point there are many technical hurdles that must be overcome, including data collection, data storage, and most importantly turning the stores of data into actionable insights.

Gastrointestinal Stromal Tumors Already Proving to Be Treatable With Targeted Therapies

Gastrointestinal Stromal Tumors, or GIST, is resistant to conventional chemotherapy drugs and radiation. This article takes a detailed look at how targeted therapies may help to overcome the many challenges care providers are faced when treating GIST.

Hepatoblastoma: A Need for Cell Lines and Tissue Banks to Develop Targeted Drug Therapies

As there is limited research regarding the most aggressive forms of hepatoblastoma, this article details many of the challenges faced in the availability of tissue and cell lines required to develop targeted therapies. While a solution is challenging to find, the problem is very well defined by this study.

Webinars & Podcasts

July 5th, 2019
Liquid Biopsy in NSCLC
August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports


June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
View all publications